An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...

A new version of the McDonald criteria — the official guidelines used to diagnose MS — aim to make MS diagnosis faster and ...

A new FDA target action date of 28 December could bring tolebrutinib’s tumultuous development period to an end.

The 2024 McDonald criteria, published just before the 2025 ECTRIMS Congress, substantially expand criteria for a probable diagnosis of multiple sclerosis, experts report.

Vidofludimus calcium currently is being evaluated in relapsing MS in two phase III trials, ENSURE-1 and ENSURE-2. The phase ...

Integrating Century Health's novel large language model (LLM) with electronic health records (EHRs) rapidly delivered 130k+ ...

Ryan Haumschild, PharmD, MS, MBA: One of the things I see is, pharmacists play an important role in treatment recommendations and follow-up as well. A lot of times when you’re counseling a patient or ...

Nebraska Medicine has become the first medical center in the world to use allogeneic CAR T-cell therapy to treat multiple ...

MILAN -- A path to a cure for multiple sclerosis (MS) may be on the horizon, a top MS researcher suggested. The field faces a great opportunity to advance from suppressing the disease to curing it, ...

Initiating treatment for multiple sclerosis (MS) within 6 months of the first symptoms is associated with a significantly lower risk for severe disability one decade later, a new study suggests.

France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...